CN116211983A - Gastrodia elata prescription medicine for treating primary dysmenorrhea and application thereof - Google Patents
Gastrodia elata prescription medicine for treating primary dysmenorrhea and application thereof Download PDFInfo
- Publication number
- CN116211983A CN116211983A CN202310059221.5A CN202310059221A CN116211983A CN 116211983 A CN116211983 A CN 116211983A CN 202310059221 A CN202310059221 A CN 202310059221A CN 116211983 A CN116211983 A CN 116211983A
- Authority
- CN
- China
- Prior art keywords
- gastrodia elata
- gastrodia
- dysmenorrhea
- primary dysmenorrhea
- prescription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010013935 Dysmenorrhoea Diseases 0.000 title claims abstract description 50
- 241000305491 Gastrodia elata Species 0.000 title claims abstract description 50
- 229940126532 prescription medicine Drugs 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 33
- 241000305492 Gastrodia Species 0.000 claims abstract description 12
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 11
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 10
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 10
- 235000013976 turmeric Nutrition 0.000 claims abstract description 10
- 240000007232 Illicium verum Species 0.000 claims abstract description 9
- 235000008227 Illicium verum Nutrition 0.000 claims abstract description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 27
- 208000002193 Pain Diseases 0.000 abstract description 23
- 208000005171 Dysmenorrhea Diseases 0.000 abstract description 19
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 abstract description 7
- 241000699670 Mus sp. Species 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical group CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 7
- 229960001680 ibuprofen Drugs 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 150000003180 prostaglandins Chemical class 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 101800000989 Oxytocin Proteins 0.000 description 5
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 5
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 5
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 5
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 5
- 230000003821 menstrual periods Effects 0.000 description 5
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 5
- 229960001723 oxytocin Drugs 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000132011 Atractylodes lancea Species 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 2
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046797 Uterine ischaemia Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229930193974 gastrodin Natural products 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000008346 uterine blood flow Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a gastrodia elata prescription medicine for treating primary dysmenorrhea, which comprises the following medicinal and edible components in parts by mass: 1-2 parts of gastrodia elata, 1 part of turmeric, 1 part of rhizoma atractylodis and 1 part of star anise; the gastrodia elata contains components such as gastrodine, gastrodine and the like, has the effects of dispelling wind and dredging collaterals, can also play a role in relieving pain, and is helpful for relieving pain when people eat gastrodia elata during dysmenorrhea. The invention applies the gastrodia tuber prescription medicine to primary dysmenorrhea, and is assisted with turmeric, rhizoma atractylodis and star anise, compared with the traditional Chinese medicine prescription or pure gastrodia tuber, the invention has better treatment effect on primary dysmenorrhea, and clinical application proves that the gastrodia tuber prescription medicine has better effect of relieving pain of dysmenorrhea.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine compositions, and particularly relates to a gastrodia elata prescription medicine for treating primary dysmenorrhea and application thereof.
Background
Primary dysmenorrhea refers to dysmenorrhea caused by non-pelvic organic diseases. Dysmenorrhea refers to pain occurring in menstrual period, often with cramping, concentrated in the lower abdomen, and may be accompanied with other symptoms including headache, nausea, vomiting, lower abdomen distention, lumbago, skelalgia, etc., and is classified into primary and secondary dysmenorrhea. The incidence of primary dysmenorrhea is 30% -80%, most of which are considered to be related to the following factors: if the age is less than 30 years old, the body mass index is low, smoking is carried out, the menstrual period is less than 12 years old, and the menstrual period is long and the menstrual period is excessive. Primary dysmenorrhea is mainly characterized in that: puberty is common, and usually occurs within 1-2 years after the beginner; pain can occur from 12 hours prior to menstruation, typically lasting 1-3 days; pain is often spastic, usually in the lower abdomen, can radiate to the lumbosacral portion and the inner side of the thigh, and can be accompanied with symptoms such as nausea, vomiting, dizziness, hypodynamia, etc.; often, primary dysmenorrhea is alleviated after pregnancy in women. The onset of primary dysmenorrhea often results in a painful and uncomfortable condition, severely affecting the work and life of the female before and after or during the menstrual period, and most of the female has a painful and uncomfortable condition caused by primary dysmenorrhea, difficulty in sleeping, work and leave-on condition, etc.
For the etiology of primary dysmenorrhea, it is currently believed that it is related to uterine structural factors, hormone secretion and calcium ion channels. Firstly, cervical stenosis and uterine buckling easily lead to isthmus tension increase, menstrual blood flows out unsmoothly, and the uterine contraction is stimulated to cause dysmenorrhea; tubular shedding of the intima is also one of the causes of primary dysmenorrhea. In vivo hormone secretion such as prostaglandin, oxytocin, vasopressin and the like can also cause spastic contraction of uterine smooth muscle, cause uterine ischemia, and cause dysmenorrhea symptoms. The increase in intracellular calcium ion concentration is also involved in the occurrence of dysmenorrhea. Previous studies have demonstrated that abnormal prostaglandin levels, which are closely related to increased prostate secretion, can cause frequent or dysrhythmic uterine contractions, thereby reducing uterine blood flow, and are considered to be a major factor in menstrual pain.
Regarding the cognition of the cause of primary dysmenorrhea, it is partly known by the mechanism of action of the drug itself after the onset of the therapeutic effect. For example, the calcium ion channel blocker agent nicardipine and the like can better relieve dysmenorrhea symptoms, so that the increase of the intracellular calcium ion concentration is presumed to be one of causes of primary dysmenorrhea. Indeed, an increase in intracellular calcium ion concentration may indeed itself cause smooth muscle contraction. Non-steroidal anti-inflammatory drugs such as aspirin and indomethacin also have certain treatment effects on primary dysmenorrhea. A common feature of non-steroidal anti-inflammatory drugs, however, is the ability to exert analgesic effects by inhibiting cyclooxygenase to block prostaglandin biosynthesis. Prostaglandins are one of the inflammatory mediators, but whether other inflammatory mediators, such as interleukins, also cause primary dysmenorrhea, is not presently clear. Because there are a large number of drugs having anti-inflammatory activity but a large number of them have no therapeutic effect on dysmenorrhea. Non-steroidal anti-inflammatory drugs have certain adverse effects on the nervous system, digestive tract system and blood system, so that the drug should be carefully administered. Contraceptive drugs can inhibit ovulation and alleviate symptoms of dysmenorrhea, but contraceptive drugs are not suitable for women with gestational or intended purpose. Because of these shortcomings of non-steroidal anti-inflammatory drugs and oral contraceptives, traditional Chinese medicine is considered a viable option for the treatment of PDM. Although the traditional Chinese medicine for treating dysmenorrhea has no western medicine, the traditional Chinese medicine has quick response, treats both principal and secondary aspect of disease and has small safety side effect, so that the traditional Chinese medicine can achieve good effect, and the traditional Chinese medicine for treating dysmenorrhea starts from the comprehensive conditioning and regulating of the human body, so that the effects of promoting blood circulation and smoothening qi and blood are achieved, and the essence and blood nourish the whole body.
The traditional Chinese medicine theory considers that the primary dysmenorrhea is related to cold congealing, qi stagnation and blood stasis, so that more blood circulation promoting and stasis removing medicines exist in the traditional Chinese medicine for treating the primary dysmenorrhea, the gastrodia elata is the dry tuber of the orchid fungus nutrition type perennial herb gastrodia elata Gastrodia elataBlume, one of the traditional rare Chinese medicinal materials in China, and the gastrodia elata has the efficacy and the effect of promoting blood circulation and removing blood stasis. Gastrodia elata can dispel external wind and also calm internal wind, so it can be used for treating wind-cold-dampness arthralgia, dizziness, tremor of limbs caused by internal movement of liver wind. Rhizoma Gastrodiae also has effects of dispelling pathogenic wind, dredging channels and relieving pain, and can be used for treating apoplexy, tibia pain, female closure, hand and foot paralysis, rheumatalgia, and joint flexion and extension disorder. Tian Ma is also combined with Chuan Xiong, etc. for headache due to pathogenic wind. In addition, tian Ma can also be used for treating hypertension, dizziness and other diseases caused by liver yang hyperactivity. Has effects of calming endogenous wind, relieving spasm, suppressing liver yang, dispelling pathogenic wind, and dredging collaterals, and can be used for treating dizziness, headache, insomnia, etc. It is recorded that the gastrodia elata has sweet and flat taste and no toxicity, and has high nutrition and health care value as a substance with homology of medicine and food. The main active ingredients in the gastrodia elata comprise gastrodin, gastrodia elata polysaccharide and the like, and modern pharmacological researches show that the gastrodia elata has the effects of calming and hypnotizing, relieving pain, resisting inflammation, resisting convulsion, resisting oxidation, resisting depression, improving memory, enhancing immunity, increasing blood flow, reducing blood pressure, resisting blood coagulation and the like. The traditional Chinese medicine turmeric is a medicine for promoting blood circulation and removing blood stasis, and has the effects of breaking blood, promoting qi circulation, dredging channels and relieving pain. Turmeric is used for treating chest and hypochondrium pain, chest pain, dysmenorrhea, amenorrhea, abdominal mass, pain of shoulder and arm due to rheumatism, and swelling and pain from traumatic injury. Curcumin in Curcuma rhizome has antiinflammatory effect, and can inhibit cyclooxygenase (COx enzyme), lipoxygenase (LOX enzyme), and prostaglandin (prostagladins). Both enzymes are associated with pain and can cause inflammation, while prostaglandins are hormones that cause uterine contractions and excessive amounts cause pain. Curcumin also can inhibit immune cells from moving to the reproductive system, and reduce inflammation. The rhizoma Atractylodis is a damp-resolving medicine, and is dried rhizome of Atractylodes lancea or Atractylodes lancea in Compositae. Rhizoma Atractylodis has effects of eliminating dampness, invigorating spleen, dispelling pathogenic wind, dispelling cold, and improving eyesight. Atractylodes lancea can produce anti-inflammatory effects by inhibiting cyclooxygenase (COx) and 5-lipoxygenase (5-LOX) activity, blocking prostaglandin, thromboxane or leukotriene synthesis. Ancient books of traditional Chinese medicine (Ben Cao Jing Shu) also describe that people with liver and kidney qi movement do not take rhizoma atractylodis, and refer to that "cover pathogenic wind-cold-dampness, enter from spleen and stomach, spleen governs muscles, and invade by pathogenic factors, so that the stomach is clear and closed, and cold-heat arthralgia is enough. The pungent and warm nature can dispel and develop the pathogenic wind-cold-dampness from the boiling theory. I.e. the Chinese herbs with pungent and warm (heat) property and spleen and stomach meridian entered should have the combined actions of warming meridians and alleviating pain and curing arthralgia due to wind-cold-dampness. The rhizoma atractylodis has pungent, bitter and warm properties, enters spleen, stomach and liver meridians, and belongs to a traditional Chinese medicine for pungent, warm (heat) combining spleen and stomach meridians, and has the effects of warming meridians to stop pain and treating wind-cold-dampness arthralgia. The fructus Anisi Stellati is dried mature fruit of fructus Anisi Stellati of Magnoliaceae. Picking fruits in autumn and winter when the fruits turn yellow from green, and drying or directly drying after scalding in boiling water. Warm nature and pungent taste, enter liver, kidney, spleen and stomach meridians. The main component of the star anise is fennel oil, which can stimulate gastrointestinal nerve and blood vessels, promote secretion of digestive juice, increase gastrointestinal peristalsis, has the effects of invigorating stomach and promoting qi circulation, and is helpful for relieving spasm and pain.
The inventor adopts a large number of animal experimental researches, adopts a primary dysmenorrhea mouse model induced by estrogen combined with oxytocin, calculates the inhibition rate of the torsion reaction of the mouse by taking the torsion reaction times and the torsion latency within 30 minutes as main observation indexes, and discovers that the gastrodia elata prescription has better pure gastrodia elata and analgesic effect.
Disclosure of Invention
The invention aims at overcoming the problems in the prior art and providing an application of a gastrodia elata prescription medicine in medicines for treating primary dysmenorrhea.
In order to achieve the aim, the invention provides a gastrodia elata prescription medicine for treating primary dysmenorrhea, which comprises the following medicinal and edible components in parts by weight: 1-2 parts of gastrodia elata, 1 part of turmeric, 1 part of rhizoma atractylodis and 1 part of star anise;
furthermore, the gastrodia elata prescription is applied to reducing the MDA expression level in serum;
furthermore, the gastrodia elata prescription is applied to reducing the expression level of relevant inflammatory factors of uterine tissues;
the beneficial effects of the invention are as follows:
the gastrodia elata contains components such as gastrodine, gastrodine and the like, has the effects of dispelling wind and dredging collaterals, can also play a role in relieving pain, and is helpful for relieving pain when people eat gastrodia elata during dysmenorrhea. The invention applies the gastrodia tuber prescription medicine to primary dysmenorrhea, and is assisted with turmeric, rhizoma atractylodis and star anise, compared with the traditional Chinese medicine prescription or pure gastrodia tuber, the invention has better treatment effect on primary dysmenorrhea, and clinical application proves that the gastrodia tuber prescription medicine has better effect of relieving pain of dysmenorrhea.
Drawings
In order to more clearly illustrate the technical solution of the embodiments of the present invention, the drawings used for describing the embodiments will be briefly described below.
FIG. 1 is a statistical chart of torsion response latency of dysmenorrhea mice according to the present invention, wherein: saline group (negative control), ibuprofen group (positive control);
FIG. 2 is a statistical chart of MDA content expression detection results in serum of mice of the invention, wherein: saline group (negative control), ibuprofen group (positive control);
FIG. 3 is a statistical chart showing the results of detection of inflammatory factor expression in uterine tissue of mice according to the present invention, wherein: saline group (negative control), ibuprofen group (positive control).
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention; the described embodiments are only some, but not all, embodiments of the invention.
Example 1
1. Constructing a primary dysmenorrhea mouse model:
the estrogens are combined with the oxytocin to construct primary dysmenorrhea model mice, and sexually mature female mice of 6-7 weeks are selected and divided into 5 groups. The experimental mice in each group except the normal control group are filled with the stomach-invigorating and Jiale in a volume of 1mL/0.1kg, the continuous administration is carried out for 10d in the morning for 1 time/d, the intraabdominal injection of oxytocin is carried out 1 hour after the end of the stomach-filling administration on the 10 th day, and the model-building mice except the normal control group have different degrees of torsion reaction, so that the animal model is successfully prepared.
2. Drug proportioning and animal drug administration:
saline control group: physiological saline;
gastrodia elata combined experimental group: taking 1-2 parts of gastrodia elata, 1 part of star anise, 1 part of turmeric and 1 part of rhizoma atractylodis; adding 800mL of water to decoct until the water amount is 100mL;
gastrodia elata experimental group: adding 4mL of physiological saline into 0.92g of rhizoma Gastrodiae powder, and making into suspension by ultrasonic treatment;
ibuprofen experimental group: 0.15g ibuprofen powder plus 4mL physiological saline;
the above groups of medicines are continuously infused into the mice for 10 days, and 10 female mice are added into each group, and the total amount of the medicines in the stomach infusion of each group is 10uL/g. The mice used in the test were SPF-grade Kunming mice purchased from SPF-grade laboratory animal center of Kunming medical university, and the laboratory animal produced license number SCXK (Yunnan) K2015-0002,6 weeks old, weight (26+ -2) g.
Example 2
Measurement of mice twist latency and number of twists:
the mice were given a corresponding amount of oxytocin solution intraperitoneally 1h after intragastric administration on day 10, and the duration of incubation for twisting and the number of twists within 30min after drug injection were started to be recorded. The results are shown in fig. 1, and compared with the model group, the torsion incubation periods of mice in the gastrodia elata composition experimental group, the gastrodia elata experimental group and the ibuprofen experimental group are prolonged, but compared with the gastrodia elata composition experimental group, the extension effect of the gastrodia elata composition experimental group is not as good as that of the gastrodia elata composition experimental group, and the experimental results show that the torsion incubation periods of the mice prolonged by the gastrodia elata composition experimental group are more remarkable. Fig. 2 shows that the number of torsion times of mice in the gastrodia elata composition experimental group, the gastrodia elata experimental group and the ibuprofen experimental group is reduced compared with the normal saline group, but the gastrodia elata composition experimental group has a lower reduction effect than the gastrodia elata composition experimental group, and the experimental result shows that the number of torsion times of the mice in the gastrodia elata composition experimental group is more remarkable.
Table 1 comparison of MDA content in mouse serum
Example 3
Detection of mouse serum MDA, uterus PGF2α, COX-2, NO content
ELISA kit is adopted for detection, and the operation process is as follows:
1. after each group of medicines are continuously infused into the stomach of a mouse for 10 days, the mouse is killed by a cervical dislocation method after the blood is taken from the eye sockets of the mouse, the following operations are carried out at 4 ℃, the taken blood is left at room temperature for half an hour, then upper serum is taken after low-speed centrifugation, the mouse uterus is put into a centrifuge tube, the mouse uterus is ground by using a handheld homogenizer, so as to obtain mouse uterus homogenate, 0.1g of mouse uterus homogenate is weighed and quickly mixed in 0.8mL of 1 XPBS, and is fully vortex to dissolve out a transmitter, 5000g is centrifuged for 10min, and ELISA experiments are carried out on the supernatant;
2. ELISA experiments were performed according to the instructions of ELISA kit (Mlbio company), and the results are shown in FIG. 2, in which MDA content in the serum of mice in the model group was increased compared with the physiological saline group; compared with the model group, the MDA content in the serum of the mice of the gastrodia elata composition experimental group, the gastrodia elata experimental group and the positive drug group is reduced, but compared with the gastrodia elata composition experimental group, the MDA reduction effect of the gastrodia elata experimental group on the MDA is lower than that of the gastrodia elata composition experimental group, and the experimental result shows that the MDA content in the serum of the mice is obviously reduced by the gastrodia elata composition experimental group.
In fig. 3, compared with the model group, the rhizoma Gastrodiae composition experimental group, the rhizoma Gastrodiae experimental group and the positive drug group have reduced intrauterine pgf2α and COX-2 contents and increased NO contents, but compared with the rhizoma Gastrodiae composition experimental group, the rhizoma Gastrodiae composition experimental group has a lower effect than the rhizoma Gastrodiae composition experimental group, and the experimental result shows that the rhizoma Gastrodiae composition experimental group has more remarkable up-regulation of the intrauterine pgf2α and COX-2 contents of the mice.
In conclusion, the gastrodia elata contains the components such as gastrodine and gastrodine, has the effects of dispelling wind and dredging collaterals, can also play a role in relieving pain, and is helpful for relieving pain when people eat gastrodia elata during dysmenorrhea. The invention applies the gastrodia tuber prescription medicine to primary dysmenorrhea, and is assisted with turmeric, rhizoma atractylodis and star anise, compared with the traditional Chinese medicine prescription or pure gastrodia tuber, the invention has better treatment effect on primary dysmenorrhea, and clinical application proves that the gastrodia tuber prescription medicine has better effect of relieving pain of dysmenorrhea.
The preferred embodiments of the invention disclosed above are merely for the purpose of helping to illustrate the invention, and the preferred embodiments do not describe all details in detail nor limit the invention to the specific embodiments described.
Claims (5)
1. The gastrodia tuber prescription medicine is characterized by comprising the following medicinal and edible materials in parts by weight: 1-2 parts of gastrodia tuber, 1 part of turmeric, 1 part of rhizoma atractylodis and 1 part of star anise.
2. The gastrodia elata prescription according to claim 1, which is characterized by comprising the following medicinal and edible components in parts by weight: 2 parts of gastrodia tuber, 1 part of turmeric, 1 part of rhizoma atractylodis and 1 part of star anise.
3. The use of the gastrodia elata prescription according to claim 1 in medicaments for treating primary dysmenorrhea.
4. Use of the gastrodia elata formula according to claim 1 for reducing MDA expression levels in serum.
5. Use of the gastrodia elata formula according to claim 1 for reducing the expression level of inflammatory factors related to uterine tissue.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310059221.5A CN116211983B (en) | 2023-01-17 | 2023-01-17 | Gastrodia elata prescription medicine for treating primary dysmenorrhea and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310059221.5A CN116211983B (en) | 2023-01-17 | 2023-01-17 | Gastrodia elata prescription medicine for treating primary dysmenorrhea and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116211983A true CN116211983A (en) | 2023-06-06 |
| CN116211983B CN116211983B (en) | 2024-05-07 |
Family
ID=86586654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310059221.5A Active CN116211983B (en) | 2023-01-17 | 2023-01-17 | Gastrodia elata prescription medicine for treating primary dysmenorrhea and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116211983B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999025368A1 (en) * | 1997-11-13 | 1999-05-27 | Ruhui Wang | A medicine for treating algomenorrhea and the method of preparation thereof |
| CN1931353A (en) * | 2006-09-27 | 2007-03-21 | 贵州师范大学 | Curcuma extract and its prepn process, medicine composition and use |
| CN103656237A (en) * | 2013-12-12 | 2014-03-26 | 陈树亮 | Gastrodia elata and red peony dysmenorrhea powder and preparation method thereof |
| CN103845348A (en) * | 2012-11-30 | 2014-06-11 | 富力 | Application of 20(R)-ginsenoside Rg3 in preparation of medicines for treating dysmenorrhea |
| CN104547818A (en) * | 2013-10-25 | 2015-04-29 | 王波 | Production technology of Hantongle Yunji and quality control method thereof |
| CN105288481A (en) * | 2015-11-19 | 2016-02-03 | 山东明仁福瑞达制药股份有限公司 | Chinese medicinal composition for treating arthromyodynia and relieving pain and preparation method of paste thereof |
| CN112439048A (en) * | 2020-12-11 | 2021-03-05 | 河南省科学院 | A Chinese medicinal composition used as both medicine and food for relieving inflammation and pain or resisting bacteria, and its preparation method |
| KR20220123832A (en) * | 2021-03-02 | 2022-09-13 | 힐링에듀팜 주식회사농업회사법인 | Food composition for improvement of dysmenorrhea symptom with natural substance |
-
2023
- 2023-01-17 CN CN202310059221.5A patent/CN116211983B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999025368A1 (en) * | 1997-11-13 | 1999-05-27 | Ruhui Wang | A medicine for treating algomenorrhea and the method of preparation thereof |
| CN1931353A (en) * | 2006-09-27 | 2007-03-21 | 贵州师范大学 | Curcuma extract and its prepn process, medicine composition and use |
| CN103845348A (en) * | 2012-11-30 | 2014-06-11 | 富力 | Application of 20(R)-ginsenoside Rg3 in preparation of medicines for treating dysmenorrhea |
| CN104547818A (en) * | 2013-10-25 | 2015-04-29 | 王波 | Production technology of Hantongle Yunji and quality control method thereof |
| CN103656237A (en) * | 2013-12-12 | 2014-03-26 | 陈树亮 | Gastrodia elata and red peony dysmenorrhea powder and preparation method thereof |
| CN105288481A (en) * | 2015-11-19 | 2016-02-03 | 山东明仁福瑞达制药股份有限公司 | Chinese medicinal composition for treating arthromyodynia and relieving pain and preparation method of paste thereof |
| CN112439048A (en) * | 2020-12-11 | 2021-03-05 | 河南省科学院 | A Chinese medicinal composition used as both medicine and food for relieving inflammation and pain or resisting bacteria, and its preparation method |
| KR20220123832A (en) * | 2021-03-02 | 2022-09-13 | 힐링에듀팜 주식회사농업회사법인 | Food composition for improvement of dysmenorrhea symptom with natural substance |
Non-Patent Citations (3)
| Title |
|---|
| 才亚贤;: "止痛中药介绍", 现代中医药, no. 05, pages 17 - 18 * |
| 王婷婷;须义贞;: "痛经中医辨证治疗", 辽宁中医药大学学报, no. 07, pages 104 - 107 * |
| 许娟;: "寒痛乐熨剂在妇科临床的应用", 内蒙古中医药, no. 15, pages 51 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116211983B (en) | 2024-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103432559B (en) | Traditional Chinese medicine composition for treating spanomenorrhea and dysmenorrhea caused by blood stasis and preparation method and application thereof | |
| CN105213941A (en) | A kind of Chinese medicine composition being used for the treatment of infantile diarrhea and preparation method thereof | |
| CN106389881A (en) | Ointment capable of invigorating blood circulation and dissipating blood stasis | |
| CN105709074A (en) | Medicine for treating rheumatic arthritis and hyperostosis and preparation method | |
| CN116211983B (en) | Gastrodia elata prescription medicine for treating primary dysmenorrhea and application thereof | |
| CN102772699B (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease | |
| CN102058808B (en) | Traditional Chinese medicament for treating rheumatic arthritis | |
| CN104587206A (en) | Medicament for treating bedsore and preparation method of medicament | |
| CN104225569A (en) | Chinese medicinal composition for treating chronic enteritis | |
| CN104288518A (en) | Traditional Chinese medicine composition for treating cervicitis | |
| CN105031505A (en) | Medicine for treating benign prostatic hyperplasia hypertrophy and preparation method thereof | |
| CN103494991B (en) | Traditional Chinese medicine preparation for treating female metrorrhagia and preparation method thereof | |
| CN102416049A (en) | Small square type rheumatoid swelling diminishing and pain eliminating plaster and preparation method thereof | |
| CN102018776B (en) | Medicine for treating gall-stone | |
| CN105963619A (en) | Traditional Chinese medicine composition for treating uterus coldness infertility | |
| CN105998781A (en) | Pharmaceutical composition for treating acute gastroenteritis | |
| CN105853782A (en) | Traditional Chinese medicinal composition for treating uterine prolapsed | |
| CN105687936A (en) | Traditional Chinese medicine composition for treating female chronic urocystitis and preparation method of traditional Chinese medicine composition | |
| CN105363005A (en) | Kadsura root-bark traditional Chinese medicinal wine | |
| CN104840530A (en) | Hemorrhoid ointment and preparation method thereof | |
| CN104491712A (en) | Traditional Chinese medicine formula for treating liver cancer, and preparation method thereof | |
| CN104257860A (en) | Drug for treating neurodermatitis | |
| CN103550591B (en) | Traditional Chinese medicine composition for treating hyperplasia of mammary glands | |
| CN116196359A (en) | Traditional Chinese medicine wine for treating rheumatism and traumatic injury and preparation method thereof | |
| CN109464557A (en) | A kind of external drug and preparation method thereof for treating osteoproliferation and spur |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |